

January 27, 2025

То

The Corporate Relations Department BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

Code: 540222

The Listing Department

National Stock Exchange of India Ltd.,

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

Mumbai – 400 051

Code: LAURUSLABS

Sub: Disclosure under Regulation 30(11) of SEBI Listing Regulations – Clarification on news article appearing in mainstream media.

Ref: E-mail received from Stock Exchanges (BSE & NSE) on January 27, 2025 seeking "Clarification/Confirmation on news item appearing in Media/Publication".

Dear Sir / madam,

As per media report, "US President Donald Trump has frozen President's Emergency Plan for AIDS Relief (PEPFAR) funding programmes for at least 90 days pending further review"

We wish to clarify as below:

The overall ARV medicine market size is ~US\$ 1.5bn which represent 10% of the total HIV financing budget annually. Overall AIDS funding is from the respective country Governments, PEPFAR, and the Global fund. Global agencies have worked well so far and controlled pandemic disease of AIDS. If at all there may be funding challenge, the Company reasonably believes it will not affect the procurement of medications.

We also understand from the media that USA again decided back to join WHO yesterday.

Based on the above the Company reasonably believes there will not be significant impact on the business.

Currently there is no such information necessitating disclosure to the stock exchanges in terms of Regulation 30 of the Listing Regulations.

Please take the above information on record.

Yours faithfully,

For Laurus Labs Limited

G. Venkateswar Reddy

Company Secretary & Compliance Officer

CIN: L24239AP2005PLC047518